AR093476A1 - Composiciones y metodos para el tratamiento de la displasia ectodermica - Google Patents

Composiciones y metodos para el tratamiento de la displasia ectodermica

Info

Publication number
AR093476A1
AR093476A1 ARP130104180A ARP130104180A AR093476A1 AR 093476 A1 AR093476 A1 AR 093476A1 AR P130104180 A ARP130104180 A AR P130104180A AR P130104180 A ARP130104180 A AR P130104180A AR 093476 A1 AR093476 A1 AR 093476A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
compositions
methods
ectodermal dysplasia
protein monomer
Prior art date
Application number
ARP130104180A
Other languages
English (en)
Inventor
M Huttner Kenneth
Kirby Neil
Schneider Pascal
Gaide Olivier
Original Assignee
Edimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edimer Pharmaceuticals Inc filed Critical Edimer Pharmaceuticals Inc
Publication of AR093476A1 publication Critical patent/AR093476A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas y métodos para el tratamiento de displasias ectodérmicas mediante la administración de agonistas de EDA (displasia ectodérmica anhidrótica), en particular EDI200. El uso de las composiciones y métodos descritos permite la dosificación terapéutica y regímenes de administración en pacientes humanos para corregir o alterar los fenotipos anormales asociadas con trastornos genéticos, en particular, XLHED (displasia ectodérmica hipodrótica ligada al X). Reivindicación 1: Una composición farmacéutica caracterizada porque comprende al menos un monómero proteico, en donde dicho monómero proteico comprende SEQ ID Nº 1 y en donde dicho al menos un monómero proteico está glicosilado en las posiciones Asn76 y Asn302, y un excipiente farmacéuticamente aceptable. Reivindicación 6: La composición farmacéutica de la reivindicación 1, caracterizada porque el excipiente farmacéuticamente aceptable es un diluyente que comprende fosfato de sodio y cloruro de sodio. Reivindicación 7: La composición farmacéutica de la reivindicación 6, caracterizada porque además comprende uno o más tensioactivos y/o detergentes. Reivindicación 8: La composición farmacéutica de la reivindicación 7, caracterizada porque además comprende polisorbato 20.
ARP130104180A 2012-11-14 2013-11-13 Composiciones y metodos para el tratamiento de la displasia ectodermica AR093476A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261726252P 2012-11-14 2012-11-14
US201361825227P 2013-05-20 2013-05-20

Publications (1)

Publication Number Publication Date
AR093476A1 true AR093476A1 (es) 2015-06-10

Family

ID=50731641

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104180A AR093476A1 (es) 2012-11-14 2013-11-13 Composiciones y metodos para el tratamiento de la displasia ectodermica

Country Status (14)

Country Link
US (1) US20160272694A1 (es)
EP (1) EP2920318A4 (es)
JP (1) JP2015536344A (es)
KR (1) KR20150099720A (es)
AR (1) AR093476A1 (es)
AU (1) AU2013344973B2 (es)
BR (1) BR112015011099A2 (es)
CA (1) CA2891386A1 (es)
IL (1) IL238602A0 (es)
MX (1) MX2015005993A (es)
RU (1) RU2015117995A (es)
SG (1) SG11201503777YA (es)
TW (1) TW201438730A (es)
WO (1) WO2014078353A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3060245B1 (en) * 2013-10-22 2020-02-26 EspoirXLHED Sàrl Intra-amniotic administration of proteins for the treatment of ectodermal dysplasias
JP2020154179A (ja) * 2019-03-20 2020-09-24 ヤフー株式会社 情報処理装置、情報処理方法および情報処理プログラム
JP2020154180A (ja) * 2019-03-20 2020-09-24 ヤフー株式会社 情報処理装置、情報処理方法および情報処理プログラム
JP2020154178A (ja) * 2019-03-20 2020-09-24 ヤフー株式会社 情報処理装置、情報処理方法および情報処理プログラム
CN114145452B (zh) * 2021-12-10 2022-11-01 青岛圣桐营养食品有限公司 特殊医学用途全营养配方食品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
AU2002333502A1 (en) * 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
US9175085B2 (en) * 2011-05-13 2015-11-03 Edimer Pharmaceuticals, Inc. Treatment of X-linked hypohidrotic ectodermal dysplasia with ectodysplasin A agonist

Also Published As

Publication number Publication date
CA2891386A1 (en) 2014-05-22
SG11201503777YA (en) 2015-06-29
KR20150099720A (ko) 2015-09-01
US20160272694A1 (en) 2016-09-22
BR112015011099A2 (pt) 2017-08-22
JP2015536344A (ja) 2015-12-21
TW201438730A (zh) 2014-10-16
AU2013344973A1 (en) 2015-05-14
WO2014078353A1 (en) 2014-05-22
MX2015005993A (es) 2015-12-09
AU2013344973B2 (en) 2016-10-06
EP2920318A1 (en) 2015-09-23
EP2920318A4 (en) 2016-04-13
RU2015117995A (ru) 2017-01-10
IL238602A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
AR093476A1 (es) Composiciones y metodos para el tratamiento de la displasia ectodermica
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
AR086409A1 (es) Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
BR112014007902A2 (pt) composições farmacêuticas compreendendo 40-o-(2-hidróxi)etil-rapamicina
MX2021002321A (es) Nuevos metodos.
RS20080497A (en) Novel low dose pharmaceutical compositions comrising nimesulide, preparation and use thereof
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
AR054442A1 (es) Formas de dosificacion, composiciones farmaceuticas y metodos para el suministro sub-tenon
AR076505A1 (es) Uso de alopurinol para el tratamiento de la reaccion cutanea en manos -pies
BR112015012497A8 (pt) combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
WO2015183984A3 (en) Therapeutic compositions including tocopherol and uses thereof
WO2015183985A3 (en) Therapeutic compositions including naphthoquinones and uses thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure